In myeloma, shared SNPs in PSMB6 and PSMB9 were associated with a decreased response to bortezomib therapy, without affecting survival, demonstrating how germline variation can influence IP-related therapeutic effects (80). This evidence concerns the gene PSMB9 and plasma cell myeloma.